SENSEX NIFTY
Feb 28, 2013, 09.36 AM IST | Source: PTI

Jubilant Life gets warning letter from USFDA

Drug firm Jubilant Life Sciences today said US health regulator has issued a warning letter for violation of manufacturing norms at its facility in Canada.

Drug firm Jubilant Life Sciences today said US health regulator has issued a warning letter for violation of manufacturing norms at its facility in Canada.

"Jubilant HollisterStier General Partnership (JHS) located at Kirkland, Quebec, Canada has been issued a warning letter (WL) by US Food and Drug Administration (FDA) identifying significant violations of current good
manufacturing practices (cGMP) regulations,"  Jubilant Life Sciences said in a filing to the BSE.

As required by FDA, JHS will respond to this letter by March 15, 2013, it added.

"The response will provide details as to what corrective action has already been completed, as well as, additional detail as to how the facility will prevent the re occurrence of the items found to be objectionable to the FDA," Jubilant Life Sciences said.

Also read: Pharma sector expects sweet pill in upcoming Budget

USFDA had specified in its letter that until all corrections have been completed, it may withhold approval of new applications or supplements listing JHS as the drug product manufacturer.

"We expect that the on-going manufacturing, distribution and sale of products will not be affected by this warning letter. JHS is committed to implementing the necessary corrective actions required to address the FDA concerns, and
will work closely with the FDA to bring resolution to this matter," it added.

Shares of Jubilant Life Sciences today closed at Rs 176.45 per scrip on BSE, down sharp 4.90 percent from its previous close.

Jubilant Life stock price

On August 22, 2014, Jubilant Life Sciences closed at Rs 167.25, down Rs 0.35, or 0.21 percent. The 52-week high of the share was Rs 222.00 and the 52-week low was Rs 66.10.


The company's trailing 12-month (TTM) EPS was at Rs 19.49 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 8.58. The latest book value of the company is Rs 108.82 per share. At current value, the price-to-book value of the company is 1.54.

Set email alert for

ADS BY GOOGLE

video of the day

See earnings growth spike, big reforms in 2015: Envision

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.